Table 5.
STI prevalence and 95% CI a among 556 FSWs b at baseline and six months after intervention, Shanghai, 2009-10
| Intervention | Control | Intervention vs. Control | AOR (95% CI) c | p-value | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| p-value | ||||||||||
| Baseline, % (n = 278) | Follow-up, % (n = 150) | p-value | Baseline, % (n = 278) | Follow-up, % (n = 200) | p-value | Baseline | Follow-up | |||
| Chlamydia | 15.8 (9.7-19.3) | 11.4 (6.8-17.6) | 0.272 | 12.2 (8.6-16.7) | 9.5 (5.8-14.4) | 0.4294 | 0.2712 | 0.6875 | 1.16 (0.57-2.33) | 0.6886 |
| Gonorrhoea | 5.8 (3.3-9.2) | 2.7 (0.74-6.7) | 0.2335 | 0.72 (0.09-2.6) | 3.0 (1.1-6.4) | 0.0731 | 0.0018 | 1.000 | 0.96 (0.30-3.09) | 0.9484 |
| Syphilis | 1.1 (0.2-3.1) | 0.67 (0.0-3.7) | 0.9177 | 1.4 (0.39-3.6) | 2.0 (0.55-5.0) | 0.725 | 1.000 | 0.3969 | 0.39 (0.06-2.73) | 0.3433 |
| Any STI | 19.8 (15.3-25.0) | 14.1 (8.9-20.7) | 0.1828 | 14.0 (10.2-18.7) | 14.5 (9.9-20.2) | 0.9898 | 0.0897 | 0.9645 | 0.94 (0.51-1.74) | 0.8398 |
a95% exact binomial confidence interval.
bRandomly selected 57 participants who were lost to follow-up in the intervention arm were added to equalize the sample sizes in the two arms.
cAdjusted odds ratio, invention group vs control group at follow-up after adjusting for baseline level and venue type, among those had a follow-up.